pharma · Diffuse Cutaneous Systemic Sclerosis · Myopia
Elan Pharmaceuticals
Elan Pharma International
Elan Pharmaceuticals clinical programs — 18 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Treasury Building, Lower Grand Canal Street, Dublin 2, IE
- Founded
- 1969
- Employees
- 792
- Programs
- 18
- Drugs
- 26
- Patents
- 0
Elan Pharmaceuticals projects
18 ClinicalTrials.gov programs sponsored by Elan Pharmaceuticals.
Elan Pharmaceuticals has 18 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
General anesthesia and opioids
Elan Pharma International
Breast Neoplasms
1 trial -
HZNP-DAZ-301
Elan Pharma International
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
1 trial -
HZNP-DAZ-303
Elan Pharma International
Sjögren’s Syndrome With Moderate-toSevere Symptom State
1 trial -
Imiquimod
Elan Pharma International
Lentigo Maligna
1 trial -
OCUS-Mode-CT-V1
Elan Pharma International
Myopia
1 trial -
TMC125
Elan Pharma International
HIV-1
1 trial -
VIB0551.P3.S1
Elan Pharma International
Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).
1 trial -
VIB0551.P3.S2
Elan Pharma International
Immunoglobulin G4-related disease (IgG4-RD)
1 trial -
Fipaxalparant
Elan Pharma International
Diffuse Cutaneous Systemic Sclerosis
1 trial -
GH001-TRD-201
Elan Pharma International
Treatment-resistant depression (TRD)
1 trial -
HZNP-DAX-202
Elan Pharma International
Primary Discoid Lupus Erythematosus
1 trial -
HZNP-HZN-1116-201
Elan Pharma International
Sjögren’s Syndrome
1 trial -
HZNP-HZN-825-301
Elan Pharma International
Diffuse Cutaneous Systemic Sclerosis
1 trial -
HZNP-HZN-825-303
Elan Pharma International
Idiopathic Pulmonary Fibrosis
1 trial -
INEBILIZUMAB
Elan Pharma International
Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])
1 trial -
TMC435
Elan Pharma International
Hepatitis C
1 trial -
WVE-006
Elan Pharma International
Alpha-1 antitrypsin deficiency (AATD)
1 trial -
A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity
Elan Pharma International
Adults Living with Overweight and Obesity
1 trial
Frequently asked questions
How many clinical projects does Elan Pharmaceuticals have?
18 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.